RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today the pricing of a registered public offering of up to 21,000,000 units consisting of shares and warrants for $1.00 per unit, or a total of up to $21 million in gross proceeds. The units consist of one share of PolyMedix common stock and a five year warrant to purchase 0.30 shares of PolyMedix common stock at $1.25 per share. The units will not be certificated and the shares and warrants will be immediately separable and transferable upon issuance. Merriman Curhan Ford (Nasdaq: MERR) acted as lead placement agent in this offering with Boenning & Scattergood, Inc. and Noble Financial Capital Markets serving as co-placement agents. Fordham Financial Management, Inc. acted as a selected dealer in the offering.
